Surgical Implications of the Potential New Tubal Pathway for Ovarian Carcinogenesis

Journal of Minimally Invasive Gynecology

Volumn 20, Issue 2, 2013, Pages 153-159

  Chene, Gautier ^a   Rahimi, Kourosh ^a   Mes Masson, Ann Marie ^a   Provencher, Diane ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

BRCA; Laparoscopy; Ovarian cancer; Ovarian dysplasia; Salpingectomy; STIC

Indexed keywords

CYCLIN E; HISTONE H2AX; LAMININ GAMMA1; PROTEIN P16; PROTEIN P53; STATHMIN;

CANCER SUSCEPTIBILITY; CARCINOGENESIS; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; MORBIDITY; OVARIECTOMY; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; RECEPTOR UPREGULATION; REVIEW;

CARCINOMA IN SITU; CELL TRANSFORMATION, NEOPLASTIC; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MUTATION; OVARIAN NEOPLASMS; SALPINGECTOMY;

EID: 84875366273     PISSN: 15534650     EISSN: 15534669     Source Type: Journal    
DOI: 10.1016/j.jmig.2012.11.010     Document Type: Review

References (81)

1. Folkins A.K., Jarboe E.A., Saleemuddin A., et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008, 109:168-173.
2. Kindelberger D., Lee Y., Hirsch M.S., et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007, 31:161-169.
3. Powell C.B., Kenley E., Chen L.M., et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 2005, 23:127-132.
4. Finch A., Shaw P., Rosen B., et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006, 100:58-64.
5. Callahan M.J., Crum C.P., Medeiros F., et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007, 25:3985-3990.
6. Leeper K., Garcia R., Swisher E., et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002, 87:52-56.
7. Medeiros F., Muto M.G., Lee Y., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006, 30:230-236.
8. Hirst J.E., Gard G.B., McIllroy K., et al. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer 2009, 19:826-829.
9. Crum C.P. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol 2009, 3:165-170.
10. Mehrad M., Ning G., Chen E.Y., et al. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the Fallopian tube. Adv Anat Pathol 2010, 17:293-302.
11. Gross A.L., Kurman R.J., Vang R., et al. Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol 2010, 2010:126295.
12. Piek J.M., van Diest P.J., Zweemer R.P. Dysplastic changes in prophylactic removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001, 195:451-456.
13. Carcangiu M.L., Radice P., Manoukian S., et al. Atypical epithelial proliferation in Fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA 1 and BRCA 2 germline mutation carriers. Int J Gynecol Pathol 2003, 23:35-40.
14. Chen E.Y., Mehra K., Mehrad M., et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube. J Pathol 2010, 222:110-116.
15. Tung C.S., Mok S.C., Tsang Y.T., et al. PAX2 expression in low malignant potential ovarian tumors and low grade ovarian serous carcinomas. Mod Pathol 2009, 22:1243-1250.
16. Roh M.H., Yassin Y., Miron A., et al. High grade fimbrial ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 2010, 23:1316-1324.
17. Chivukula M., Dabbs D.J., O'Connor S., et al. PAX2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma. Int J Gynecol Pathol 2009, 28:570-578.
18. Kuhn E., Kurman R.J., Vang R., et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012, 226:421-426.
19. Salvador S., Rempel A., Soslow R.A., et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol 2008, 110:408-417.
20. Sehdev A.S., Kurman R.J., Kuhn E., et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including RSF-1 (HBXAP), Cyclin E and fatty acid synthase. Mod Pathol 2010, 23:844-855.
21. Karst A.M., Levanon K., Duraisamy S., et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011, 123:5-12.
22. Kuhn E., Kurman R.J., Soslow R.A., et al. The diagnostic and biological implications of Laminin expression in serous tubal intraepithelial carcinoma. Am J Surg Pathol 2012, 36:1826-1834.
23. Kuhn E., Meeker A., Wang T.L., et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010, 34:829-836.
24. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.
25. Bartkova J., Horejsí Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
26. Mah L.J., El-Osta A., Karagiannis T.C. γH2AX as a molecular marker of aging and disease. Epigenetics 2010, 2:129-136.
27. Clingen P.H., Wu J.Y.H., Miller J., et al. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Bioch Pharmacol 2008, 76:19-27.
28. Karst A.M., Levanon K., Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. PNAS 2011, 108:7547-7552.
29. Kim J., Coffey D.M., Creighton C.J., et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 2012, 109:3921-3926.
30. Przybycin C.G., Kurman R.J., Ronnett B.M., et al. Are all pelvic (Non uterine) serous carcinomas of tubal origine?. Am J Surg Pathol 2010, 34:1407-1416.
31. Carlson J.W., Miron A., Jarboe E.A., et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 2008, 26:4160-4165.
32. Roh M.H., Kindelberger D., Crum C.P. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?. Am J Surg Pathol 2009, 33:376-383.
33. Seidman J.D., Zhao P., Yemelyanova A. Primary peritoneal high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011, 120:470-473.
34. Leonhardt K., Einenkel J., Sohr S., et al. P53 Signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol 2011, 30:417-424.
35. Deligdisch L. Ovarian dysplasia: a review. Int J Gynecol Cancer 1997, 7:89-94.
36. Salazar H., Godwin A.K., Daly M.B., et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996, 88:1810-1820.
37. Werness B.A., Afify A.M., Bielat K.L., et al. Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 1999, 30:151-157.
38. Stratton J.F., Buckey C.H., Lowe D., et al. Comparison of prophylactic oophorectomy specimens from carriers and non carriers of a BRCA1 or BRCA2 gene mutation. J Natl Cancer Inst 1999, 91:626-628.
39. Chene G., Penault-Llorca F., Le Bouedec G., et al. Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. Int J Gynecol Cancer 2009, 19:65-72.
40. Deligdisch L., Gil J. Characterization of ovarian dysplasia by interactive morphometry. Cancer 1989, 63:748-755.
41. Deligdisch L., Miranda C., Barba J. Ovarian dysplasia: nuclear texture analysis. Cancer 1993, 72:3253-3257.
42. Lauchlan S.C. The secondary Mullerian system. Obstet Gynecol Surv 1972, 27:133-146.
43. Auersperg N. The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol 2010, 30:12-21.
44. Crum C.P., McKeon F.D., Xian W. BRCA, the oviduct and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer 2012, 22:S29-S34.
45. Kuhn E., Kurman R.J., Shih I.M. Ovarian cancer is an imported disease: fact or fiction?. Curr Obstet Gynecol Rep 2012, 1:1-9.
46. Cibula D., Widschwendter M., Majek O., et al. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Hum Reprod Update 2011, 17:55-67.
47. Antoniou A.C., Rookus M., Andrieu N., et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA 1 and BRCA 2 mutation carriers; results from the international BRCA 1/2 carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009, 18:601-610.
48. Dietl J., Wischhusen J. The forgotten fallopian tube. Nat Rev Cancer 2011, 11:227.
49. Dietl J., Wischhusen J., Hausler S.F.M. The post-reproductive Fallopian tube: better removed?. Human Reprod 2011, 26:2918-2924.
50. Wan T.S., Chan L.C., Ngan H.Y., et al. High frequency of telomeric associations in human ovarian surface epithelial cells transformed by HPV oncogenes. Cancer Genet Cytogenet 1997, 95:166-172.
51. Trottier A.M., Provencher D., Mes-Masson A.M., et al. Absence of human papillomavirus sequences in ovarian pathologies. J Clin Microbiol 1995, 33:1011-1013.
52. Lai C.H., Wang C.Y., Lin C.Y., et al. Detection of HPV RNA in ovarian and endometrial carcinomas by reverse transcription polymerase chain reaction. Gynecol Obstet Invest 1994, 38:276-280.
53. Savelieva E., Belair C.D., Newton M.A., et al. 20q gain associates with immortalization; 20q 13.2 amplification correlates with genome instability in HPV 16 E7 transformed human uroepithelial cells. Oncogene 1997, 14:551-560.
54. Altinoz M.A., Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase inhibitions as likely mechanisms behind the acetaminophen and NSAID prevention of the ovarian cancer. Neoplasma 2004, 51:239-247.
55. Leblanc E., Narducci F., Farre I., et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA1 or 2 genes? Rationale and preliminary development. Gynecol Oncol 2011, 121:472-476.
56. Healthcare cost and utilization project (HCUP), 1988-2001: a federal-state-industry partnership in health data. Rockville, MD: Agency for healthcare research and quality. Available at:. http://www.cdc.gov/mnwr/preview/mmwhrtml/ss5105a1.htm.
57. Determinants of hysterectomy and oophorectomy in women attending menopause clinics in Italy. Maturitas 2000, 36:19-25. Progetto menopausa italia study group 1.
58. Parker W.H. Bilateral oophorectomy versus ovarian conservation: effects on long-term women's heath. J Minim Invasive Gynecol 2010, 17:161-166.
59. Parker W.H., Broder M.S., Chang E. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet Gynecol 2009, 113:1027-1037.
60. Bartz D., Greenberg J.A. Sterilization in the United States. Rev Obstet Gynecol 2008, 1:23-32.
61. Chene G., Raoelfils I., Dauplat J., et al. Don't forget Fallopian tubes: a morphologic and immunohistochemical study about Fallopian tubes with genetic risk (BRCA mutation). Gynecol Obstet Fertil 2012, 40:14-18.
62. Landon G., Stewart J., Deavers M., et al. Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility. Gynecol Oncol 2012, 125:683-686.
63. Manchanda R., Drapkin R., Jacobs I., et al. The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecol Oncol 2012, 124:185-191.
64. Colgan T.J., Boerner S.L., Murphy J., et al. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 2002, 85:397-403.
65. Paley P.J., Swisher E.M., Garcia R.L., et al. Occult cancer of the fallopian tube in BRCA1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001, 80:176-180.
66. Chene G., Penault-Llorca F., Le Bouedec G., et al. Ovarian epithelial dysplasia: myth or reality?. Gynecol Obstet Fertil 2008, 36:800-807.
67. Tone A.A., Salvador S., Finlayson S.J., et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012, 10:296-306.
68. Domchek S.M., Friebel T.M., Singer C.F., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975.
69. Kauff N.D., Satagopan J.M., Robson M.E. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609-1615.
70. Struewing J.P., Watson P., Easton D.F., et al. Prophylactic oophorectomy in inherited breast/ovarian cancer familie. J Natl Cancer Inst Monogr 1995, 17:33-35.
71. Piver M.S., Jishi M.F., Tsukada Y., et al. Primary peritoneal carcinoma afetr prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993, 71:2751-2755.
72. Cass I., Walts A., Karlan B.Y. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?. Gynecol Oncol 2010, 117:27-31.
73. Gerritzen L.H., Grefte J.M., Hoogerbrugge N., et al. A substancial part of the fallopian tube is left after standard prophylactic bilateral salpingo-oophorectomy. Int J Gynecol Cancer 2006, 16:1940-1944.
74. Manchanda R., Silvanto A., Abdelraheim A., et al. Diathermy-induced injury may affect detection of occult yubal lesions at risk-reducing salpingo-oophorectomy. Int J Gynecol Cancer 2012, 22:881-888.
75. Rabban J.T., Krasik E., Chen L.M., et al. Multistep level sections to detect occult fallopian tube carcinomas in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol 2009, 33:1878-1885.
76. Deligdisch L. Optical biopsy in gynecology. Bull Acad Natl Med 2011, 195:605-611.
77. Ascencio M., Collinet P., Cosson M., et al. The place of confocal microscopy in gynecology. J Gynecol Obstet Biol Reprod 2008, 37:64-71.
78. Tanbakuchi A.A., Udovich J.A., Rouse A.R., et al. In vivo imaging of ovarian tissue using a novel confocal microlaparoscope. Am J Obstet Gynecol 2010, 202:90.e1-90.e9.
79. McAlpine J.N., El Hallani S., Lam S.F., et al. Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: a promising step towards screening and early detection. Gynecol Oncol 2011, 120:385-392.
80. Collins I.M., Domchek S.M., Huntsman D.G., et al. The tubal hypothesis of ovarian cancer: caution needed. Lancet Oncol 2011, 12:1089-1091.
81. Chene G., Penault-Llorca F., Robin N., et al. Early detection of ovarian cancer: tomorrow?. J Gynecol Obstet Biol Reprod 2012, S0368-2315(12)00334-1.